Regulus Therapeutics (RGLS)
(Delayed Data from NSDQ)
$1.79 USD
-0.24 (-11.85%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $1.78 -0.01 (-0.28%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
Regulus Therapeutics Inc. [RGLS]
Reports for Purchase
Showing records 1 - 20 ( 272 total )
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
1Q24 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Phase 1b ADPKD Trial Advances to Cohort 4; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
2023 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Dose Response and TKV Reduction in ADPKD Study Cohort 2; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Third Cohort of the Phase 1b ADPKD Study Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Genomic Medicine Deep Dive-Redrawing Frontiers at the Coding Level
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
3Q23 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Patient Dosing Commences in Cohort 3 of Phase 1b MAD Study; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Phase 1b MAD Study Reports Positive Cohort 1 Topline Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Phase 1b MAD Study Completes Cohort 2 Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
2Q23 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Phase 1b ADPKD Trial Starts Patient Dosing in Second Cohort; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Preclinical Program For ALS Advances to Lead Compound Evaluation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
1Q23 Financial Results; Competitive Landscape Improves; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Phase 1b Study First Cohort Completes Enrollment; Financing Closed; Reiterate Buy; Lowering PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Phase 1b MAD Study of RGLS8429 Starts Patient Dosing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
2Q22 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Partner?s Alport Syndrome Program Terminated; Reit. Buy; Reverse Stock Split Leads to $20 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
RGLS8429 Receives Orphan Drug Designation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
First Subject Dosed in Phase 1 Trial of RGLS8429; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R